ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview

Adc Therapeutics

11/08/2026 14:02

ADC Therapeutics SA ADCT.N, ADCT.K is expected to  show a rise in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026
The Epalinges Vaud-based  company is expected to report a 2.8% increase in revenue to $19.376 million from $18.84 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
​LSEG's mean analyst estimate for ADC Therapeutics SA is for a loss of 21 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for ADC Therapeutics SA is $2.00, about 77% above its last closing price of $1.13
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.21
-0.21
-0.13
Beat
39.5
Dec. 31 2026
-0.25
-0.27
-0.04
Beat
85.1
Sep. 30 2025
-0.36
-0.36
-0.30
Beat
17.1​
Jun. 30 2025
-0.48
-0.47
-0.38
Beat
19.8
​​Mar. 31 2025
-0.39
-0.40
-0.36
Beat
10.7
Dec. 31 2024
-0.44
-0.41
-0.29
Beat
29.6​
Sep. 30 2024
-0.36
-0.39
-0.42
Missed
-6.3
Jun. 30 2024
-0.45
-0.46
-0.38
Beat
16.9
This summary was machine generated August 11 at 13:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)